- Home
- CNEY vs TCBP Comparison
CNEY vs TCBP Comparison
Compare CNEY & TCBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNEY
- TCBP
- Stock Information
- Founded
- CNEY 2018
- TCBP 2013
- Country
- CNEY China
- TCBP United Kingdom
- Employees
- CNEY N/A
- TCBP N/A
- Industry
- CNEY Major Chemicals
- TCBP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CNEY Industrials
- TCBP Health Care
- Exchange
- CNEY Nasdaq
- TCBP Nasdaq
- Market Cap
- CNEY 1.0M
- TCBP 1.3M
- IPO Year
- CNEY 2021
- TCBP 2022
- Fundamental
- Price
- CNEY $0.24
- TCBP $2.50
- Analyst Decision
- CNEY
- TCBP Strong Buy
- Analyst Count
- CNEY 0
- TCBP 1
- Target Price
- CNEY N/A
- TCBP $48.00
- AVG Volume (30 Days)
- CNEY 1.9M
- TCBP 473.7K
- Earning Date
- CNEY 01-01-0001
- TCBP 11-25-2024
- Dividend Yield
- CNEY N/A
- TCBP N/A
- EPS Growth
- CNEY N/A
- TCBP N/A
- EPS
- CNEY N/A
- TCBP N/A
- Revenue
- CNEY $50,957,974.00
- TCBP N/A
- Revenue This Year
- CNEY N/A
- TCBP N/A
- Revenue Next Year
- CNEY N/A
- TCBP N/A
- P/E Ratio
- CNEY N/A
- TCBP N/A
- Revenue Growth
- CNEY N/A
- TCBP N/A
- 52 Week Low
- CNEY $0.22
- TCBP $2.03
- 52 Week High
- CNEY $1.60
- TCBP $523.20
- Technical
- Relative Strength Index (RSI)
- CNEY 42.98
- TCBP 28.65
- Support Level
- CNEY $0.23
- TCBP $2.03
- Resistance Level
- CNEY $0.28
- TCBP $2.68
- Average True Range (ATR)
- CNEY 0.02
- TCBP 0.90
- MACD
- CNEY 0.00
- TCBP -0.02
- Stochastic Oscillator
- CNEY 43.70
- TCBP 8.79
About CNEY CN Energy Group Inc.
CN Energy Group Inc along with its subsidiaries is a manufacturer and supplier of wood-based activated carbon that is used in pharmaceutical manufacturing, industrial manufacturing, water purification, environmental protection, and food and beverage production and a producer of biomass electricity generated in the process of producing activated carbon. The firm generates a majority of its revenue from Activated carbon.
About TCBP TC BioPharm (Holdings) plc
TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled the company to develop a range of clinical-stage cell therapies designed to combat cancer and viral infection.